Skip to content

CAMP4 Therapeutics Corporation

CAMP

CIK 0001736730

← back to feed
Revenue (TTM)
$3.15M
Q1 May 2026
Net Income (TTM)
−$58.45M
−55.2% YoY Q1 May 2026
EPS Diluted (TTM)
−$2.11
+76.0% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
-1,677.8%
Q1 May 2026
Net Margin
-1,855.6%
Q1 May 2026
Free Cash Flow (TTM)
−$29.83M
Q1 May 2026
Cash
$99.21M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
51.93M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings